Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Taliglucerase Alfa
Therapeutic Area : Genetic Disease
Study Phase : Undisclosed
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Assessing the Impact of Elelyso on Bone Involvement Currently Treated With Other ERTs
Details : Undisclosed
Product Name : Elelyso
Product Type : Enzyme
Upfront Cash : Inapplicable
April 20, 2020
Lead Product(s) : Taliglucerase Alfa
Therapeutic Area : Genetic Disease
Highest Development Status : Undisclosed
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Taliglucerase Alfa
Therapeutic Area : Genetic Disease
Study Phase : Phase IV
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Elelyso
Product Type : Enzyme
Upfront Cash : Inapplicable
July 01, 2019
Lead Product(s) : Taliglucerase Alfa
Therapeutic Area : Genetic Disease
Highest Development Status : Phase IV
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Taliglucerase Alfa
Therapeutic Area : Genetic Disease
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
January 16, 2017
Lead Product(s) : Taliglucerase Alfa
Therapeutic Area : Genetic Disease
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Taliglucerase Alfa
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Multicenter Extension Study of Taliglucerase Alfa in Adult Subjects With Gaucher Disease
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
August 23, 2011
Lead Product(s) : Taliglucerase Alfa
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Taliglucerase Alfa
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Multicenter Extension Study of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
August 08, 2011
Lead Product(s) : Taliglucerase Alfa
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Taliglucerase Alfa
Therapeutic Area : Genetic Disease
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
May 28, 2010
Lead Product(s) : Taliglucerase Alfa
Therapeutic Area : Genetic Disease
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable